Releases - MOBERG DERMA AB

The Swedish pharmaceutical company, Moberg Derma, which focuses on skin diseases, today announced that it is strengthening its organization by appointing Tommy Nilsson as the new CEO. Peter Wolpert, Moberg Derma’s current CEO and one of the company’s founders, will stay on as working Vice Chairman of the Board, focusing on international partnerships and investor relations.

”We are continuously working on...

The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, is today reporting positive data from its clinical phase II trial involving the K301 product candidate. K301, which is based on the patented Kaprolac® principle, is a new non-steroid topical treatment for seborrheic dermatitis of the scalp. In the trial, two different formulations of K301 were tested against placebo. 76 percent of...

The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, has started recruiting patients for a clinical phase III trial of the K101 product candidate to treat nail fungus (onychomycosis). The company plans to include 470 patients in the study at around 40 clinics in Sweden and Poland. Results from the trial are expected in the second half of 2008.

”This is Moberg Derma’s first clinical...

Stockholm, Sweden, June 27, 2007
The Swedish pharmaceutical company Moberg Derma AB today announced that it has received approval from the Swedish Medical Products Agency (MPA) to initiate a clinical multi-centre phase III trial for its novel nail fungus project K101. The trial will include up to 470 patients in Sweden and in at least one more country. Patient enrolment is planned to start in September 2007, and...

Stockholm, Sweden June 27th, 2007

The Swedish pharmaceutical company Moberg Derma AB, today announced that it has successfully completed the financing of SEK 27,7 million. The Baltic Sea Foundation (Östersjöstiftelsen) was the lead investor and was joined by other institutional and private investors, as well as members of management.

“We are very satisfied with the interest and support from investors. The...